EKF Profit Narrows To £3 Mln In H1; Plans Re-brand Of Contract Manufacturing Business
(RTTNews) – EKF Diagnostics Holdings plc (EKF.L), a diagnostics company, released on Tuesday interim financial results for the six months ending June 30, 2026. Profit for the half-year period decreased mildly as sales showed consistent growth.
The company provides various devices for use at point-of-care facilities in analyzing blood sugar or hemoglobin levels, in addition to diagnostic enzymes and tests for immune, infectious, and oncological diseases.
H1 Financial Highlights:
EKF’s profit before income tax narrowed to £3.42 million in the first half of 2026, slightly lower than the £3.63 million reported in the same period of 2025.
Revenues reached £25.03 million, a mild decrease from the £25.24 million recorded in the previous year.
Sales of the company’s Beta-HB LiquiColour reagent grew by 4%, while gains on contract manufacturing rose by 25%.
Profit for the period was £2.48 million or £0.54 per share, higher than the £2.10 million or £0.43 per share reported a year ago.
EBITDA resulted in a gain of £5.92 million, compared to £5.77 million in 2025.
Cash and cash equivalents as of June 30, 2026, amounted to £15.97 million.
Outlook:
The company mentioned a long-term outlook, with revenues anticipated to be over £80 million by 2029, supporting an estimated EBITDA gain of £20 million.
Business Updates:
As part of a new strategy, the company plans to spin off its Contract Manufacturing business under a new brand name, Nexus Bioworks.
The Hemo Control portion of consumable sales shows potential for extended manufacturing, planned for implementation in 2027.
EKF.L is currently trading on the London Stock Exchange at £25.60, down 1.54%.
